Tag - ENTA

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...